AKT1 and Zika virus infectious disease: We have demonstrated that exposure of DMAQ-B1 and AKT inhibitor VIII through either continuous exposure (Fig 2) or a single treatment (Fig 3) was sufficient to induce activation of both antiviral pathways independently of ZIKV infection.